|
Piper Jaffray Reiterates “Neutral” Rating for Biogen Idec (BIIB)
Watch List News (press release) … in particular unpublished estimates) now fully reflect Tecfidera’s strong launch, in our view, and upside in BIIB shares will likely require pipeline success, which is not expected until 2014 data readouts from anti-LINGO Phase II (optic neuritis … |
|
JIM – Un nouvel anticorps monoclonal pour le traitement de la sclérose en plaques
Journal International de Médecine (Inscription) Ainsi, le daclizumab est un anticorps monoclonal humanisé spécifique du récepteur CD25 diminuant l’activation immunitaire via l’interleukine 2. Plus de 600 patients ont été inclus dans l’étude SELECT, randomisée, en double aveugle et contre placebo … |
|
BioInvent extends collaboration for the discovery and development of …
PharmiWeb.com (press release) BioInvent International AB (OMXS: BINV) today announces that it has signed an extension to its 2009 license agreement with Mitsubishi Tanabe Pharma Corporation for the development of antibodies from BioInvent’s n-CoDeR® library. Under the terms of … |
|
BioInvent extends collaboration for the discovery and development of …
PipelineReview.com (press release) LUND, Sweden I July 2, 2013 I BioInvent International AB (OMXS: BINV) today announces that it has signed an extension to its 2009 license agreement with Mitsubishi Tanabe Pharma Corporation for the development of antibodies from BioInvent’s … |
|
BioInvent extends collaboration for the discovery and development of …
Fort Mills Times BioInvent International AB (OMXS: BINV) today announces that it has signed an extension to its 2009 license agreement with Mitsubishi Tanabe Pharma Corporation for the development of antibodies from BioInvent’s n-CoDeR® library. Under the terms of the … |
|
NICE issues second draft guidance on the use of Pixuvri as monotherapy to …
pharmabiz.com The European Medicines Agency’s (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have … |
3 Oncology, Medical University Clinic, Kantonsspital Baselland, Liestal …Journal of Nuclear Medicine (subscription)The aim of this study was to determine the maximum tolerated dose (MTD) and to explore the clinical response to 177Lu-DOTA-rituximab in…
|
Stock Analysts’ Ratings Reiterations for July, 1st (AMP, BBRY, BIIB, COH, CRM …
Zolmax … in particular unpublished estimates) now fully reflect Tecfidera’s strong launch, in our view, and upside in BIIB shares will likely require pipeline success, which is not expected until 2014 data readouts from anti-LINGO Phase II (optic neuritis … |
Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 – Market …Sacramento BeeThe currently marketed monoclonal antibodies are clinically and commercially highly successful products in the rheumatoid arthritis market, constituting four of the …
|
Biogen Idec Stock Rating Reaffirmed by Piper Jaffray (BIIB)
Zolmax … in particular unpublished estimates) now fully reflect Tecfidera’s strong launch, in our view, and upside in BIIB shares will likely require pipeline success, which is not expected until 2014 data readouts from anti-LINGO Phase II (optic neuritis … |